| Standard not met | Reason | Action being taken by the Pharmacy | By when | Notification By Pharmacy Improvements Made |
|---|---|---|---|---|
| 1.1 | The pharmacy carries out checks on the prescribers that it receives private prescriptions from. But these checks don’t include the clinics they work for, and whether they are subject to regulation. The pharmacy has not considered the extra risks associated with clinics that are not regulated. So it cannot provide assurances that the service providers it works with are operating safely and effectively. |
We are implementing a structured clinic onboarding and verification process. All new clinics will be required to: ● Confirm whether they are regulated (e.g. CQC) ● Provide regulatory registration details where applicable ● Provide a prescribing policy or complete a structured governance questionnaire. Clinics will be categorised based on regulatory status, with enhanced due diligence applied where appropriate, including sample-based review to provide further assurance. For existing clinics, we are undertaking a phased review: ● Priority will be given to recently active clinics ● Clinics will be contacted to provide updated governance and verification information |
29/04/2026 | |
| 4.2 | The pharmacy requires prescribers to submit additional information when prescribing weight-loss injections and botulinum toxins. But the pharmacy doesn’t make any checks on the accuracy of the information provided. And its team members do not always take the opportunity to make a clinical intervention based on the information provided to them to make sure the treatment is safe for people to use. This means there is a risk that some medicines could be supplied inappropriately. |
We are strengthening clinical checks through the introduction of structured safeguards and clearer intervention processes. Immediate actions include: ● Introduction of a visual flagging system (e.g. red triangle marker) on prescriptions to highlight higher-risk items requiring additional pharmacist review ● Focused checks on key risk areas, including: - Address mismatch (where patient, delivery and prescriber addresses differ) - Multiple use of the same delivery address - Patients linked to multiple delivery addresses - BMI outside expected thresholds - Incorrect starting doses - Inappropriate or rapid dose escalation Pharmacists will be required to actively review flagged prescriptions and take appropriate action where concerns are identified. Intervention recording is already in place and will continue to be used to document clinical queries and outcomes. A structured escalation process to the Superintendent Pharmacist is being formalised to ensure consistent handling of higher-risk cases. Further system improvements are planned to enhance intervention recording and oversight, including: ● Clearer documentation of communication with clinics ● Clear recording of clinic responses ● Improved ability to review and search interventions ● Clearer recording of escalation decisions These enhancements will be implemented as part of ongoing system development. Training: Pharmacists will complete additional training in weight management and GLP-1 therapies (e.g. CPPE modules), alongside internal training focused on: ● Identifying prescribing risks ● Appropriate intervention and escalation ● Use of updated processes and safeguards |
29/04/2026 |
Pharmacy inspections
Inspection reports and learning from inspections